Redhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by Roth Capital
Redhill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “buy” rating restated by equities researchers at Roth Capital in a report issued on Wednesday. They currently have a $27.00 target price on the biotechnology company’s stock. Roth Capital’s price objective would indicate a potential upside of 187.54% from the stock’s previous close.
Several other research firms also recently issued reports on RDHL. HC Wainwright raised their price target on shares of Redhill Biopharma from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Redhill Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. UBS AG assumed coverage on Redhill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating for the company. Finally, FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Redhill Biopharma has an average rating of “Hold” and an average target price of $24.44.
Shares of Redhill Biopharma (RDHL) traded up 4.8488% during midday trading on Wednesday, hitting $9.8453. The company had a trading volume of 173,254 shares. Redhill Biopharma has a one year low of $8.16 and a one year high of $14.74. The stock’s 50-day moving average price is $8.88 and its 200-day moving average price is $9.33. The stock’s market capitalization is $168.97 million.
Redhill Biopharma (NASDAQ:RDHL) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The business had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. Analysts predict that Redhill Biopharma will post ($2.36) EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the 1st quarter valued at approximately $101,000. Family Management Corp acquired a new position in shares of Redhill Biopharma in the 1st quarter worth approximately $163,000. Oppenheimer & Co. Inc. lifted its position in shares of Redhill Biopharma by 36.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 6,172 shares during the period. Jane Street Group LLC acquired a new position in shares of Redhill Biopharma in the 1st quarter worth approximately $276,000. Finally, D.A. Davidson & CO. lifted its position in shares of Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares during the period. 10.99% of the stock is owned by institutional investors and hedge funds.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.